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Manchester, Stoke-on-Trent, Worcester, Middlesbrough, and Birmingham, United KingdomObjectives This study sought to investigate the inﬂuence of access site utilization on mortality, major
adverse cardiac and cardiovascular events (MACCE), bleeding, and vascular complications in a large
number of patients treated by primary percutaneous coronary intervention (PPCI) in the United
Kingdom over a 5-year period, through analysis of the British Cardiovascular Intervention Society
database.
Background Despite advances in antithrombotic and antiplatelet therapy, bleeding complications
remain an important cause of morbidity and mortality in patients with acute ST-segment elevation
myocardial infarction (STEMI) undergoing PPCI. A signiﬁcant proportion of such bleeding
complications are related to the access site, and adoption of radial access may reduce these
complications. These beneﬁts have not previously been studied in a large unselected national
population of PPCI patients.
Methods Mortality (30-day), MACCE (a composite of 30-day mortality and in-hospital myocardial
re-infarction, target vessel revascularization, and cerebrovascular events), and bleeding and access site
complications were studied based on transfemoral access (TFA) and transradial access (TRA) site
utilization in PPCI STEMI patients. The inﬂuence of access site selection was studied in 46,128 PPCI
patients; TFA was used in 28,091 patients and TRA in 18,037. Data were adjusted for potential
confounders using Cox regression that accounted for the propensity to undergo radial or femoral
approach.
Results TRA was independently associated with a lower 30-day mortality (hazard ratio [HR]: 0.71, 95%
conﬁdence interval [CI]: 0.52 to 0.97; p < 0.05), in-hospital MACCE (HR: 0.73, 95% CI: 0.57 to 0.93;
p < 0.05), major bleeding (HR: 0.37, 95% CI: 0.18 to 0.74; p < 0.01), and access site complications
(HR: 0.38, 95% CI: 0.19 to 0.75; p < 0.01).
Conclusions This analysis of a large number of PPCI procedures demonstrates that utilization of TRA is
independently associated with major reductions in mortality, MACCE, major bleeding, and vascular
complication rates. (J Am Coll Cardiol Intv 2013;6:698–706) ª 2013 by the American College of
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699Primary percutaneous coronary intervention (PPCI) repre-
sents the current gold standard reperfusion strategy in the
setting of acute ST-segment elevation myocardial infarction
(STEMI) (1,2). Advances in antithrombotic therapy have
improved the prognosis of patients presenting with STEMI by
reducing ischemic events and mortality (3), although this has
been at the expense of increased procedure-related bleeding
complications. Such procedure-related bleeding complications
are independently associated with adverse events, including
30-day mortality, reinfarction, and stroke (4–6). Recent
studies evaluating new antithrombotic therapies have focused
on the reduction of bleeding events as a major therapeutic goal
(7–9). Patients with STEMI undergoing percutaneous coro-See page 707
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TRA = transradial accessnary intervention (PCI) are at high risk for the development of
such bleeding complications. For example, data from the
National Heart, Lung, and Blood Institute Dynamic Registry
have documented a signiﬁcant increase in bleeding and
transfusions in patients presenting with STEMI compared
with those with non-STEMI (10). A signiﬁcant proportion of
thesemajor bleeding complications are related to the access site
(11), and adoption of the transradial access (TRA) site in
patients undergoingPCI has been shown to reduce access site–
related bleeding complications in selected populations (12).
The recent randomized controlled trial RIFLE-STEACS
(Radial versus Femoral Randomized Investigation in ST
Elevation Acute Coronary Syndrome) suggests that adoption
of the transradial route may be associated with a reduction in
cardiac mortality, MACCE (major adverse cardiac and
cerebrovascular events), and access site–related bleeding
complications in patients presenting with STEMI (13),
whereas a recent meta-analysis of randomized controlled
studies suggested that the TRA is associated with a 47%
reduction in mortality and a 38% reduction in major adverse
cardiac events in STEMI patients undergoing PCI (14).
These randomized controlled trials that have studied the
inﬂuence of access site on outcomes in patients undergoing
STEMI PCI are relatively small in size and have excluded
many high-risk patient groups such as those presenting
with cardiogenic shock (15–19), elderly patients (15), and
those with previous coronary artery bypass grafting (CABG)
(15–18), hence, the applicability of such data to real-world
practice remains unclear. Furthermore, previous data derived
from randomized controlled studies in STEMI PCI patients
often include a signiﬁcant proportion of rescue and facilitated
PCI cases (16,17,19), hence, its applicability to the PPCI
setting remains uncertain. We have therefore analyzed
outcomes from a large observational database of primary PCI
cases performed in the United Kingdom over a 5-year period,
to investigate the relationship between access site practice andoutcomes in a nonselected, high-risk, real-world cohort of
patients.
Methods
The British Cardiovascular Intervention Society database.
The British Cardiovascular Intervention Society (BCIS)
was formed in 1988 to collect PCI data relating to the
nationwidepractice of PCI in theUnitedKingdom.From1988
to 1991, annual national PCI data were published in theBritish
Heart Journal whereas annual reports from 1992 onwards are
available for download from the society’s website. The data are
collected via theCentralCardiacAuditDatabase (20)under the
auspices of the National Institute
of Cardiovascular Outcomes
Research (NICOR). The aim of
the BCIS-NICOR database is to
record all PCI procedures per-
formed in any hospital in
the United Kingdom (England,
Scotland, Wales, and Northern
Ireland). In 2009, 97% of all
PCI procedures performed in
National Health Service hospitals
in England and Wales had been
entered into the database.
The BCIS-NICOR database
records clinical, procedural, and
outcome information with a total
of 113 variables collected and
available in the form of an Excel
spreadsheet (Microsoft, Red-
mond,Washington). Information
recorded in the database includes
patient demographic features,
indications for PCI, procedural
details, and outcome data (20). As
of March 2010, there were
approximately 460,000 records in
the BCIS database, with approxi-
mately 80,000 new records being
added each year. Mortality tracking is undertaken by the
Medical Research Information Service using patients’
National Health Service number that provides a unique
identiﬁer for any person registered with the National Health
Service in England and Wales.
Study deﬁnitions. PPCI procedures performed in patients
presenting with STEMI in the United Kingdom between
January 1, 2006, and December 31, 2010, were analyzed in
this study. Patients who underwent PCI through the left or
right femoral artery or the left or right radial artery were
included in the femoral and radial cohorts, respectively. The
primary outcomes examined were 30-day mortality and
Figure 1. Study Sample Selection From the BCIS Dataset
Sample selection from the British Cardiovascular Intervention Society
(BCIS) dataset illustrating patient inclusion and exclusion from analysis.
PCI ¼ percutaneous coronary intervention.
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700MACCE (a composite of 30-day mortality and in-hospital
myocardial re-infarction, target vessel revascularization, and
cerebrovascular events). Total mortality was deﬁned as
mortality up to the date of latest census (December 31,
2010). In-hospital major bleeding complications were
deﬁned as gastrointestinal bleed, intracerebral bleed, retro-
peritoneal hematoma, blood or platelet transfusion, or an
arterial access site complication requiring surgery. An access
site complication was deﬁned as a hematoma that delayed
discharge, a pseudoaneurysm, retroperitoneal hematoma, or
any other vascular complication requiring surgery.
Statistical analysis. Continuous variables are presented as
means  SD. Chi-square tests were used for analysis of
categorical variables, and Student t tests were used to analyze
continuous variables. The relationship of baseline variables
with 30-day mortality, MACCE, access site complications,
and bleeding was assessed with stepwise logistic regression
with univariable and multivariable analysis. Factors thought
to be important for the endpoints were entered for the
analysis, and this model included: age, sex, diabetes, hy-
pertension, hypercholesterolemia, family history, smoking
status, shock, left ventricular function, intra-aortic balloon
pump (IABP) use, previous acute myocardial infarction
(AMI), previous CABG, thrombectomy catheter, year of
procedure, and glycoprotein (GP) IIb/IIIa use. Variables
that were found to be signiﬁcant on univariate analysis for
the endpoints of 30-day mortality, MACCE, access site
complications, and bleeding (p < 0.05) were then entered
into the multivariate stepwise logistic regression model.
Kaplan-Meier cumulative survival and MACCE curves were
constructed and compared by the log-rank test. To further
account for confounding variables and bias, propensity
matching was performed on the study cohort. A logistic
regression model was ﬁt for access site use (radial vs.
femoral) to patient demographics. Variables included in the
logistic regression model to calculate the propensity score
were age, sex, diabetes, hypertension, hypercholesterolemia,
peripheral vascular disease, previous cerebral vascular acci-
dent, renal failure, previous AMI, previous PCI, previous
CABG, cardiogenic shock, IABP, and ventilation. Pro-
pensity score matching was performed using nearest-
neighbor matching with a caliper of 0.05. The Hansen and
Bowers balance test p value was 0.659, showing good co-
variate balance. Cox proportional hazards regression models
were used in the propensity-matched cohort to calculate the
adjusted hazard ratio (HR).
All statistical tests were 2-tailed. A value of p < 0.05 was
used to indicate statistical signiﬁcance. Statistical analysis
was performed using MedCalc version 10.4 (MedCalc
Software, Mariakerke, Belgium), SPSS (version 19.0, SPSS-
MAC, Chicago, Illinois), and Kaplan Meier curves were
constructed with Prism 5 for Mac (GraftPad Software,
La Jolla, California).Results
Primary PCI cohort and changes in access site utilization over
time. A total of 48,603 PPCI procedures were performed in
patients presenting with STEMI in the United Kingdom
between January 1, 2006, and December 31, 2010, of which
46,128 procedures utilized a single access route and were
included in further analysis (Fig. 1). Transfemoral access
(TFA) was utilized in 28,091 patients (60.9%), whereas
TRA was used in 18,037 patients (39.1%). Figures 2A and
2B illustrate the trends in access site use for PPCI between
the years 2006 and 2010. In 2006, only 12.5% of all PPCI
cases were performed via TRA, whereas by 2010, access site
practice had evolved rapidly so that TRA accounted for
49.5% of all cases.
Procedural characteristics and demographics. Table 1 details
demographic features of patients undergoing PPCI through
either the TRA site or the TFA site. Procedural character-
istics are summarized in Table 2. Of note, TRA patients
were more likely to receive GP IIb/IIIa receptor inhibitor
therapy or be treated with thrombectomy devices, whereas
TFA patients had more graft PCI, shock, and IABP use.
Relationship between access site and mortality outcomes.
Total mortality (at date of latest census, August 2011, when
mean follow up was 668.8  502.4 days (mean  SD) was
5,013 of 46,128 (10.9%), of which 3,812 of 28,091 (13.6%)
occurred in those cases that were performed through the TFA
site, whereas 1,201 of 18,037 (6.7%) occurred in those cases
that were performed through the TRA site (p < 0.0001).
Thirty-day mortality was 2,331 of 46,128 (5.1%) of which
1,875 of 28,091 (6.7%) occurred in those cases performed
though the TFA site, whereas 456 of 18,037 (2.5%)
Figure 2. Utilization of the Radial and Femoral Access Sites During PPCI
(January 2006 to December 2010)
(A) Number of cases of radial (solid columns) and femoral access (open
columns) site utilization during primary percutaneous coronary intervention
(PPCI) (2006 to 2010). (B) Percent of cases of radial (solid columns) and
femoral access (open columns) site utilization during PPCI (2006 to 2010).
Table 1. Baseline Clinical Demographics for Radial and Femoral
Access Sites
Variable Radial (n ¼ 18,037) Femoral (n ¼ 28,091) p Value
Age, yrs 62.6  14.2 63.7  13.2 <0.05
Male 13,731 (76.1%) 20,454 (72.8%) <0.001
Diabetes 2,210 (12.3%) 4,196 (14.9%) <0.001
Hypertension 7,232 (40.1%) 10,775 (38.4%) <0.001
Hypercholesterolemia 7,558 (41.9%) 10,736 (38.2%) <0.001
Previous AMI 2,023 (11.2%) 3,957 (14.1%) <0.001
Previous CABG 195 (1.1%) 991 (3.5%) <0.001
Family history 6,321 (35.0%) 8,854 (31.5%) 0.66
Smoking
Current 7,517 (41.6%) 9,730 (34.6%) <0.001
Ex-smoker 4,171 (23.1%) 6,557 (23.3%) 0.59
Never smoked 4,867 (26.9%) 7,429 (26.4%) 0.20
PVD 589 (3.3%) 893 (3.2%) 0.61
Values are means  SD or n (%).
AMI ¼ acute myocardial infarction; CABG ¼ coronary bypass grafting; PVD ¼ peripheral
vascular disease.
Table 2. Procedural Characteristics for Radial and Femoral Access Sites
Variable
Radial
(n ¼ 18,037)
Femoral
(n ¼ 28,091) p Value
GP IIb/IIIa 12,621 (65.7%) 18,159 (62.8%) <0.001
Target vessel
LAD 7,963 (44.1%) 12,568 (44.7%) 0.21
LCX 2,858 (15.8%) 4,454 (15.9%) 0.98
RCA 7,716 (42.7%) 11,676 (41.6%) 0.10
LMS 222 (1.2%) 600 (2.1%) <0.001
Grafts 233 (1.3%) 697 (2.5%) <0.001
Thrombectomy devices 7,370 (40.9%) 8,639 (30.6%) <0.001
Cardiogenic shock 576 (3.2%) 2,264 (8.1%) <0.001
IABP 384 (2.1%) 1947 (6.0%) <0.001
DES use 7,820 (43.4%) 12,139 (43.2%) 0.75
Number of stents used 1.39  0.88 1.43  1.00 <0.05
Values are means  SD or n (%).
DES ¼ drug-eluting stent; GP ¼ glycoprotein; IABP ¼ intra-aortic balloon pump; LAD ¼ left
anterior descending coronary artery; LCX ¼ left circumﬂex artery; RCA ¼ right coronary artery.
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701occurred in those cases performed through the TRA site
(p < 0.0001). Figure 3 illustrates Kaplan-Meier unadjusted
survival curves for both the TFA and TRA site groups, with
a statistically signiﬁcant decrease in mortality associated with
the use of TRA (HR: 0.66, 95% conﬁdence interval [CI]:
0.62 to 0.70; p < 0.0001 [unadjusted]; HR: 0.79, 95% CI:
0.74 to 0.85; p < 0.0001 [multivariate adjusted for baseline
procedural and baseline characteristics] log rank test).
Multivariate stepwise logistic regression analysis adjusted
for baseline procedural and demographic characteristics
demonstrated that TRA was independently associated with
a reduction in 30-day mortality (HR: 0.71, 95% CI: 0.52 to
0.97; p < 0.05). Table 3 illustrates other independent pre-
dictors of 30-day mortality following adjustments of baseline
covariates. Figure 4 illustrates 30-day mortality rates over
time, from 2006 until 2010, and for the individual TRA
and TFA cohorts over the same time period. Thirty-daymortality decreased from 5.75% in 2006 to 4.68% in 2010,
which may in part reﬂect the increase in TRA utilization
from 12.5% in 2006 to 49.5% in 2010.
Relationship between access site and MACCE outcomes.
MACCE was 2,158 of 28,091 (7.7%) in those cases per-
formed through the TFA site and 616 of 18,037 (3.4%) in
cases performed through the TRA (p < 0.001). Table 4
illustrates individual components of MACCE. Multivariate
stepwise logistic regression analysis adjusted for baseline
procedural and demographic characteristics demonstrated
that TRA was independently associated with a reduction
of in-hospital MACCE (HR: 0.73, 95% CI: 0.57 to 0.93;
p < 0.05). Table 5 illustrates independent predictors of
MACCE following adjustments of baseline covariates.
Figure 3. Kaplan-Meier Survival Curve for Mortality in Patients With
STEMI Undergoing PPCI According to Access Site Utilization
Kaplan-Meier survival curve for mortality in patients with STEMI undergoing
PPCI according to access site utilization. The solid line represents the
femoral access site, and the broken line represents the radial access site.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; PPCI ¼ primary percutaneous
coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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702Relationship between access site and access site complica-
tions and major bleeding outcomes. A total of 295 (0.64%)
in-hospital major bleeding events were recorded, of which
260 occurred in those cases performed through the TFA site
(0.93%) and 35 occurred in those cases performed through
the TRA site (0.19%); p < 0.0001. Multivariate stepwise
logistic regression analysis adjusted for baseline procedural
and demographic characteristics demonstrated that TRA
was independently associated with a reduction of in-hospital
major bleeding complications (HR: 0.37, 95% CI: 0.18 to
0.74; p < 0.01). Finally, a total of 273 arterial access site
complications (0.59%) were recorded, of which 204 occurred
in those cases performed through the TFA site (0.72%) and
69 through the TRA site (0.38%); p < 0.0001; following
multivariate stepwise logistic regression analysis adjusted
for baseline procedural and demographic characteristics,Table 3. Multivariate Predictors of 30-Day Mortality
Variable HR (95% CI)* p Value
Access site (radial) 0.71 (0.52–0.97) <0.05
Age, yrs 1.05 (1.04–1.06) <0.0001
No GP IIb/IIIa 1.43 (1.07–1.90) <0.05
Severe LV dysfunction 6.23 (4.67–8.30) <0.0001
Shock 5.10 (3.62–7.18) <0.0001
IABP use 3.07 (2.15–4.40) <0.0001
*Adjusted for age, sex, diabetes, hypertension, hypercholesterolemia, smoking status, shock,
family history, intra-aortic balloon pump use, previous AMI, previous CABG, thrombectomy
catheter, left ventricular (LV) function, year of procedure, and GP IIb/IIIa use.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.TRA was independently associated with a reduction of
access site complications (HR: 0.38, 95% CI: 0.19 to 0.75;
p < 0.01).
Propensity score matching andmortality and MACCE outcomes.
To further account for confounding variables and bias in our
study cohort, propensity score matching was performed to
adjust for differences in clinical baseline variables (age, sex,
diabetes, hypertension, hypercholesterolemia, peripheral
vascular disease, previous cerebral vascular accident, renal
failure, previous AMI, previous PCI, previous CABG,
cardiogenic shock, IABP, and ventilation), producing a total
of 24,710 patients (12,355 in the TFA group and 12,355 in
the TRA group). Table 6 illustrates the baseline demo-
graphics were well balanced in the 2 propensity-matched
cohorts. Thirty-day mortality in the propensity-matched
cohort was 449 of 12,355 (3.6%) in those cases performed
though the TFA site, whereas 304 of 12,355 (2.5%)
occurred in those cases performed through the TRA site
(p < 0.0001). Cox multivariate regression analysis was
performed adjusting for baseline characteristics, and TRA
was independently associated with a reduction in 30-day
mortality (HR: 0.67, 95% CI: 0.60 to 0.79; p < 0.0001).
MACCE was 565 of 12,355 (4.6%) in the propensity-
matched TFA cohort and 430 of 12,355 (3.5%) in the TRA
cohort (p< 0.0001). Cox multivariate regression analysis was
performed adjusting for baseline characteristics, and TRA
was independently associated with a reduction in 30-day
MACCE (HR: 0.80, 95% CI: 0.70 to 0.92; p < 0.005).
Discussion
In the current analysis of 46,128 PPCI cases recorded in the
BCIS database over a 5-year period, our data suggest that
TRA is independently associatedwith lower rates ofmortality,
MACCE, bleeding, and vascular complications. We also
demonstrate that TRA is now extensively utilized for arterial
access in the setting of primary PCI in the United Kingdom.
Signiﬁcant progress in the management of STEMI has
occurred in the last decade, leading to appreciable im-
provements in the prognosis associated with this condition
(21), led in part through advances in antithrombotic therapy
that reduce ischemic events and mortality (3). This has been
at the expense of increased procedure-related bleeding com-
plications, which are independently associated with adverse
outcomes (22,23). A signiﬁcant proportion of these major
bleeding complications are related to the access site (11,19),
a major determinant of which is use of the femoral artery
during PCI (24). Reduction of bleeding complications during
PCI is an important therapeutic strategy in improving
outcomes during PCI. Treatments that reduce the risk of
bleeding, but retain efﬁcacy similar to that of standard
treatment, have shown reductions in mortality in acute
coronary syndromes (8,25). Similarly, adoption of TRA in
patients undergoing PCI has been also been shown to reduce
Figure 4. PPCI 30-Day Mortality (%) Between 2006 and 2010 for Radial, Femoral, and Combined Cohort
PPCI 30-day mortality (%) between 2006 and 2010 for radial (solid columns), femoral (open columns), and combined (hatched columns) cohort.
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703major bleeding complications (6,26) and may have an impact
on mortality (27).
Our study suggests that adoption of TRA in the setting
of PPCI is independently associated with a signiﬁcant
reduction in mortality and MACCE outcomes, with an
associated 60% reduction in major bleeding complications,
and a 70% reduction in major access site complications. This
is in keeping with outcomes derived from previous small,
observational and randomized studies reporting outcomes in
PPCI related to access site selection (28–31). Analysis of
the Scottish Coronary Revascularization Register of 4,534
patients undergoing primary or rescue PCI has shown that
use of the TRA site was associated with reduced access site
bleeding complications (adjusted odds ratio [OR]: 0.21,
95% CI: 0.08 to 0.56; p < 0.002), myocardial infarction
(adjusted OR: 0.66, 95% CI: 0.51 to 0.87; p < 0.003), and
30-day mortality (adjusted OR: 0.51, 95% CI: 0.04 to 0.52;
p < 0.001), with differences in myocardial infarction and
death remaining signiﬁcant up to 9 years of follow-up (31).Table 4. MACCE
Variable
Radial
(n ¼ 18,037)
Femoral
(n ¼ 28,091) p Value
MACCE 616 (3.4%) 2,158 (7.7%) <0.001
Death at 30 days 456 (2.5%) 1,875 (6.7%) <0.001
Reinfarction 60 (0.3%) 131 (0.5%) 0.10
Reintervention 87 (0.5%) 169 (0.6%) 0.09
TIA or stroke 47 (0.3%) 92 (0.3%) 0.20
Values are n (%).
MACCE ¼ major adverse cardiac and cardiovascular events; TIA ¼ transient ischemic attack.Similarly, analysis of the North American National Cardio-
vascular Data Registry CathPCI registry that included
90,879 who underwent either primary or rescue PCI for
STEMI showed that TRA was independently associated
with reduction of in-hospital mortality (OR: 0.76, 95%
CI: 0.57 to 0.99) and of bleeding (OR: 0.62, 95% CI: 0.53
to 0.72) (32). The recently published RIVAL (RadIal
Vs femorAL access for coronary intervention) randomized
multicenter trial (19) demonstrated a statistically signiﬁcant
40% reduction in the primary endpoint (death, myocardial
infarction, stroke, or non-coronary artery bypass graft–related
major bleeding), and a 61% reduction in overall mortality
in the STEMI subgroup associated with TRA. Similarly,
in the HORIZONS-AMI (Harmonizing Outcomes with
RevasculariZatiON and Stents in Acute Myocardial In-
farction) trial, TRA was associated with a 55% reduction in
the rate of non-CABG–related major bleeding rates and
a 77% reduction in death or reinfarction at 30 days (33).Table 5. Multivariate Predictors of In-Hospital MACCE
Variable HR (95% CI)* p Value
Access site (radial) 0.73 (0.57–0.93) <0.05
Age, yrs 1.04 (1.03–1.05) <0.0001
No GP IIb/IIIa 1.40 (1.11–1.76) <0.005
Severe LV dysfunction 4.48 (3.54–5.66) <0.0001
Shock 4.10 (3.06–5.50) <0.0001
IABP use 2.96 (2.18–4.04) <0.0001
*Adjusted for age, sex, diabetes, hypertension, hypercholesterolemia, smoking status, shock,
intra-aortic balloon pump use, previous AMI, previous CABG, thrombectomy catheter, LV
function, year of procedure, and GP IIb/IIIa use.
Abbreviations as in Tables 1, 2, 3, and 4.
Table 6. Baseline Clinical Demographics for Radial and Femoral
Access Sites in Propensity-Matched Cohort
Variable
Radial
(n ¼ 12,355)
Femoral
(n ¼ 12,355) p Value
Age, yrs 62.9  13.0 62.3  15.1 0.69
Male 9,512 (77.0%) 9,490 (76.8%) 0.74
Diabetes 1,411 (11.4%) 1,461 (11.8%) 0.32
Hypertension 4,955 (40.1%) 5,063 (41.0%) 0.16
HCholesterol 5,424 (43.9%) 5,555 (45.0%) 0.09
PVD 358 (2.9%) 378 (3.1%) 0.45
Previous CVA 453 (3.7%) 466 (3.8%) 0.66
Renal failure 28 (0.2%) 36 (0.3%) 0.32
Previous MI 1,430 (11.6%) 1,429 (11.6%) 0.98
Previous PCI 923 (7.5%) 885 (7.2%) 0.35
Previous CABG 126 (1.0%) 111 (0.9%) 0.33
Cardiogenic shock 390 (3.2%) 371 (3.0%) 0.48
IABP 230 (1.9%) 241 (2.0%) 0.61
Ventilated 130 (1.1%) 140 (1.1%) 0.54
Values are n (%).
CVA ¼ cerebral vascular accident; HCholesterol ¼ hypercholesteremia; MI ¼ myocardial
infarction; PCI ¼ percutaneous coronary intervention; other abbreviations as in Tables 1 and 2.
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704The recent randomized controlled trial RIFLE-STEACS
(Radial versus Femoral Randomized Investigation in ST
Elevation Acute Coronary Syndrome) study has also shown
that adoption of the transradial route is associated with a
reduction in cardiac mortality, MACCE, and access site–
related bleeding complications in patients presenting with
STEMI (13). Similarly, a recent meta-analysis of 9 random-
ized controlled studies involving 2,977 patients demonstrat-
ed that TRA PCI was associated with similar reductions
in mortality (OR: 0.53, 95% CI: 0.33 to 0.84; p ¼ 0.008)
and MACCE (OR: 0.62, 95% CI: 0.43 to 0.90; p ¼ 0.012)
with trends towards a signiﬁcant reduction in major bleed-
ing events (OR: 0.63, 95% CI: 0.35 to 1.12; p ¼ 0.12) (14).
The mechanism by which TRA exerts these favorable
effects in PPCI may be related in part to the reduction in both
major bleeding and access site complications that we have
documented. Large access site bleeds can lead to hemody-
namic instability and blood transfusion with an associated
range of deleterious consequences. Although some access site
complications will not result in substantial blood loss, they
may still require intervention with consequent activation of
systemic inﬂammation and coagulation and compromised
antiplatelet regimens. This results in a disproportionate risk
of cardiovascular events even though the initial insult is not
hemodynamically signiﬁcant. Bleeding or access site com-
plications can also lead to withdrawal of antiplatelet agents,
increasing the risk of ischemic complications. The 0.7%
absolute reduction in major bleeding and 0.3% absolute
reduction in access site–related complications associated with
TRA utilization cannot, however, fully explain the magnitude
of the mortality beneﬁt associated with TRA in PPCI that we
have observed. Our major bleeding and access site–relatedcomplication event rates that we report are signiﬁcantly lower
than those reported in contemporary randomized trials that
include STEMI patients (13,19,25), which may reﬂect
under-reporting of such complications in our dataset. It is
therefore possible that the real magnitude of major bleeding
and access site complication reduction associated with the
TRA is signiﬁcantly greater than captured in our BCIS
dataset, which may account for the magnitude of mortality
beneﬁt observed to be associated with TRA. Furthermore,
our analysis indicates that the patients treated via TRA had
a greater use of thrombus aspiration and GP IIb/IIIa usage.
Use of these speciﬁc strategies may also indicate that the TRA
operators were more likely to change practice in line with
emerging data, resulting in improved outcomes through the
delivery of a more contemporary evidence-based practice.
Major practice-changing advances in the treatment of
STEMI have occurred over the past few decades that have led
to improvements in mortality outcomes. Thrombolysis has
been shown to reducemortality in STEMI by the order of 25%
(34); when compared with thrombolysis, PPCI has been
shown to reducemortality in STEMI by the order of 40% (35).
These reductions in STEMI mortality are of a similar
magnitude to the reduction in mortality that we have observed
to be associated with TRA in the current study (29%) and in
our recent meta-analysis of randomized controlled studies
(48%) (14). Although thrombolysis and PPCI strategies were
widely adopted for the management of STEMI, adoption of
TRA has been slow in some countries, despite the existing
favorable data. This may reﬂect the small sample size and
selective nature of previous studies. We have now conﬁrmed
the ﬁndings of these studies in a large, nonselected, real-world
analysis of over 40,000 PPCI procedures. Our ﬁndings have
important implications for the optimal delivery of PPCI, and
support use of the TRA as the current gold standard access site.
Our analysis has several strengths. The BCIS dataset
includes an almost complete collection of all PCI procedures
performed in the United Kingdom. This dataset, therefore,
includes all comers and reﬂects a national, real-world
experience that includes many high-risk patients encoun-
tered in daily interventional practice who are often excluded
from randomized controlled trials. Furthermore, given that
this analysis reﬂects the U.K. experience, it includes over
40,000 PPCI procedures and so represents the largest
analysis of access site–related outcomes in PPCI procedures
in the literature to date.
Study limitations. Although mortality tracking within the
United Kingdom is very robust, which is particularly
appropriate for interventions aimed at reducing mortality
such as PPCI, the cause of death is not currently available,
and all other outcomes and complications are self-reported
and are not formally audited by BCIS. This may account for
the relatively low incidence of both major bleeding and access
site complication events reported in our dataset. Therefore,
the analysis is subject to reporting biases, and complications
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705may be underreported. Furthermore, higher-risk patients
(e.g., those with cardiogenic shock) were more likely to be
managed using TFA, resulting in case-selection bias
(although cardiogenic shock was adjusted for in the multi-
variable analysis); and although propensity score matching
was performed to account for confounding variable and bias,
there is a possibility of unmeasured confounders and there-
fore residual bias. We observed a reduction in major bleeding
complications although the BCIS dataset does not collect
data utilizing bleeding deﬁnitions that are known to have
different implications on prognosis in other studies.
Although we did not have access to door-to-balloon time
data and although the reduction in bleeding/vascular
complications observed with adoption of the radial approach
should be balanced with maintaining rapid reperfusion,
previous data have suggested that door-to-balloon times are
not signiﬁcantly increased through adoption of TRA in the
PPCI setting (36). Although these data are very compelling,
caution should be exercised regarding the preferential choice
of the radial artery as an access site in PPCI cases by indi-
viduals at the very start of their transradial learning curve with
little or no previous transradial experience. Finally, our
analysis is of observational data and so cannot be used to infer
a causal relationship between access site and outcomes,
because unmeasured confounders might account for some of
the differences in outcomes observed despite the inclusion of
multiple procedural and demographic factors in our multi-
variate regression analysis and propensity score matching.
Conclusions
The current analysis of data derived from the BCIS database
of 46,128 PPCI procedures performed in the United
Kingdom over a 5-year period demonstrates that, compared
with the TFA, the TRA is independently associated with
lower mortality and MACCE rates, similar in magnitude to
the mortality beneﬁts associated with the introduction of
thrombolysis and primary PCI in the management of
STEMI. Although our analysis of an observational database
can never infer causality, the observations are consistent with
previous smaller and more selective randomized trials that
support the preferential use of TRA for PPCI.Reprint requests and correspondence: Dr Mamas A. Mamas,
Cardiovascular Institute, University of Manchester, Oxford
Road, Manchester, M13 9WL, United Kingdom. E-mail:
mamasmamas1@yahoo.co.uk.REFERENCES
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